Subject selection [Design Issues]

posted by ele2008  – Korea, 2014-10-23 07:25 (4267 d 08:43 ago) – Posting: # 13772
Views: 28,063

(edited on 2014-10-23 10:55)

Thank you for the intriguing discussion.

I posted this issue because my professor proposed we conduct such a study: to attest whether this genotype-dependancy of WSV exists or not, and if it does exist, is it same for different CYP enzymes?

So his original intention was to reduce WSV (and hence the sample size) by recruiting genetically-homogeneous subjects.

However, after reading the discussion, I wonder if it is still worth doing so (my first question).

Currently, what I am doing is to search for references and to find out if WSV is genotype-dependent. Because there are not so many papers, I decided to find papers on drug-drug interaction (DDI) studies which included genetic information. Because I read your lecture that says WSV can also be estimated from DDI studies.

But I wonder how different this estimation is from their real WSV that is determined from a replicate study or a BE study (my second question).

I appreciate very much all opinions and comments here, also if you are interested in participating our study or have any better ideas, please feel free to share with me.


Edit: I removed your e-mail address and activated the link to the contact form in your profile. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
319 visitors (0 registered, 319 guests [including 23 identified bots]).
Forum time: 16:09 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5